HK1243930A1 - 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法 - Google Patents
作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法Info
- Publication number
- HK1243930A1 HK1243930A1 HK18103427.7A HK18103427A HK1243930A1 HK 1243930 A1 HK1243930 A1 HK 1243930A1 HK 18103427 A HK18103427 A HK 18103427A HK 1243930 A1 HK1243930 A1 HK 1243930A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fxr
- methods
- bile acid
- acid analogs
- tgr5 agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076323P | 2014-11-06 | 2014-11-06 | |
| US201562107725P | 2015-01-26 | 2015-01-26 | |
| PCT/US2015/059308 WO2016073767A1 (en) | 2014-11-06 | 2015-11-05 | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1243930A1 true HK1243930A1 (zh) | 2018-07-27 |
Family
ID=55909823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18103427.7A HK1243930A1 (zh) | 2014-11-06 | 2018-03-12 | 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10266560B2 (zh) |
| EP (1) | EP3215179A4 (zh) |
| JP (1) | JP2017533923A (zh) |
| KR (1) | KR20170094184A (zh) |
| CN (1) | CN106999551A (zh) |
| AU (1) | AU2015343025A1 (zh) |
| BR (1) | BR112017009657A2 (zh) |
| CA (1) | CA2966885A1 (zh) |
| HK (1) | HK1243930A1 (zh) |
| MX (1) | MX2017005935A (zh) |
| PH (1) | PH12017500828A1 (zh) |
| RU (1) | RU2017118569A (zh) |
| SG (1) | SG11201703717SA (zh) |
| WO (1) | WO2016073767A1 (zh) |
| ZA (1) | ZA201703759B (zh) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| EA033445B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| EP3221331B1 (en) | 2014-11-19 | 2019-09-18 | Nzp Uk Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators |
| CN107108688B (zh) | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| SG11201706089RA (en) | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| RU2712099C2 (ru) | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения |
| CN107250150B (zh) * | 2015-04-28 | 2019-11-22 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201155A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201152A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| KR20190056436A (ko) | 2016-10-04 | 2019-05-24 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| US10584145B2 (en) | 2016-11-29 | 2020-03-10 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| JP2020508316A (ja) | 2017-02-21 | 2020-03-19 | ジェンフィＧｅｎｆｉｔ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| CA3055581C (en) | 2017-03-28 | 2023-03-14 | Gilead Sciences, Inc. | Methods of treating liver disease |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| WO2018237350A1 (en) | 2017-06-23 | 2018-12-27 | Intercept Pharmaceuticals, Inc. | METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| HRP20240265T1 (hr) | 2019-01-15 | 2024-05-10 | Gilead Sciences, Inc. | Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže |
| US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
| US20230146782A1 (en) * | 2019-08-06 | 2023-05-11 | Du Jessica Xinyun | Deoxycholic acid compounds, pharmaceutical compositions and uses thereof |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1592791A (en) | 1977-01-07 | 1981-07-08 | Radiochemical Centre Ltd | Selenium- or tellurium-containing bile acids and derivatives thereof |
| US4917826A (en) | 1985-10-18 | 1990-04-17 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
| IT1255485B (it) | 1992-08-04 | 1995-11-06 | Erregierre Ind Chim | Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica |
| TW289020B (zh) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| TW289757B (zh) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| BR9507200A (pt) | 1994-03-25 | 1997-09-16 | Isotechnika Inc | Melhora da eficácia de drogas por deuteração |
| US5646316A (en) | 1994-04-08 | 1997-07-08 | Osteoarthritis Sciences, Inc. | Bile acid inhibitors of metalloproteinase enzymes |
| JPH1160594A (ja) | 1997-08-25 | 1999-03-02 | Sankyo Co Ltd | 胆汁酸誘導体 |
| JP3865890B2 (ja) | 1997-09-30 | 2007-01-10 | 富士フイルムホールディングス株式会社 | ポジ型感光性組成物 |
| DE69940958D1 (de) * | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| US20020098999A1 (en) | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
| US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| ITMI20021080A1 (it) | 2002-05-21 | 2003-11-21 | Marcello Izzo | Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| HUE032928T2 (hu) | 2004-03-12 | 2017-11-28 | Intercept Pharmaceuticals Inc | Fibrózis kezelése FXR-ligandumok alkalmazásával |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2010517931A (ja) | 2006-02-14 | 2010-05-27 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体 |
| AU2007230991A1 (en) * | 2006-03-22 | 2007-10-04 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with ER stress |
| CA2656320C (en) * | 2006-06-27 | 2015-04-28 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions |
| EP2044100A2 (en) * | 2006-07-17 | 2009-04-08 | Novartis AG | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| WO2008091540A2 (en) * | 2007-01-19 | 2008-07-31 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as tgr5 modulators and methods of use thereof |
| EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| US8338628B2 (en) * | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| CA2922021C (en) | 2007-09-06 | 2018-01-09 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
| US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| CN102325784B (zh) * | 2008-11-19 | 2014-11-19 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
| CA2842707A1 (en) * | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pancreatitis |
| US11154559B2 (en) | 2011-09-29 | 2021-10-26 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
| AU2013256362A1 (en) | 2012-05-01 | 2014-11-13 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and FXR agonists: compositions and methods of use |
| DK3336097T3 (da) | 2012-06-19 | 2020-09-28 | Intercept Pharmaceuticals Inc | Fremstilling af ikke-krystallinsk obeticholsyre |
| WO2014036379A2 (en) | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| PT3360881T (pt) | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x |
| JP6556129B2 (ja) | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| EP3149019B1 (en) | 2014-05-29 | 2019-12-04 | Bar Pharmaceuticals S.r.l. | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US20160176917A1 (en) | 2014-11-26 | 2016-06-23 | Enanta Pharmaceuticals, Inc. | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| SG11201706089RA (en) | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| RU2712099C2 (ru) | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения |
| WO2016173493A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai De Novo Pharmatech Co. Ltd. | Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof |
| CN107250150B (zh) | 2015-04-28 | 2019-11-22 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
| CN107531743B (zh) | 2015-04-29 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 鹅去氧胆酸衍生物 |
| JP2018522054A (ja) | 2015-08-07 | 2018-08-09 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸およびその誘導体の調製のための方法 |
| CN105175473B (zh) | 2015-08-19 | 2018-12-21 | 丽珠医药集团股份有限公司 | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| MX2018003649A (es) | 2015-09-24 | 2018-05-11 | Intercept Pharmaceuticals Inc | Metodos e intermedios para la preparacion de derivados de acido biliar. |
| AR106293A1 (es) | 2015-10-07 | 2018-01-03 | Intercept Pharmaceuticals Inc | Moduladores del receptor x farnesoide |
| BR112018015474A2 (zh) | 2016-01-28 | 2018-12-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Steroid Derivatives FXR Agonists |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| US10815267B2 (en) | 2016-03-11 | 2020-10-27 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| US10584145B2 (en) | 2016-11-29 | 2020-03-10 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
-
2015
- 2015-11-05 RU RU2017118569A patent/RU2017118569A/ru not_active Application Discontinuation
- 2015-11-05 JP JP2017525117A patent/JP2017533923A/ja active Pending
- 2015-11-05 MX MX2017005935A patent/MX2017005935A/es unknown
- 2015-11-05 EP EP15857079.6A patent/EP3215179A4/en not_active Withdrawn
- 2015-11-05 AU AU2015343025A patent/AU2015343025A1/en not_active Abandoned
- 2015-11-05 SG SG11201703717SA patent/SG11201703717SA/en unknown
- 2015-11-05 BR BR112017009657-9A patent/BR112017009657A2/pt not_active Application Discontinuation
- 2015-11-05 WO PCT/US2015/059308 patent/WO2016073767A1/en active Application Filing
- 2015-11-05 CN CN201580066490.8A patent/CN106999551A/zh active Pending
- 2015-11-05 CA CA2966885A patent/CA2966885A1/en not_active Abandoned
- 2015-11-05 KR KR1020177015414A patent/KR20170094184A/ko unknown
- 2015-11-05 US US14/934,122 patent/US10266560B2/en active Active
-
2017
- 2017-05-04 PH PH12017500828A patent/PH12017500828A1/en unknown
- 2017-06-01 ZA ZA2017/03759A patent/ZA201703759B/en unknown
-
2018
- 2018-03-12 HK HK18103427.7A patent/HK1243930A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3215179A1 (en) | 2017-09-13 |
| ZA201703759B (en) | 2019-09-25 |
| CN106999551A (zh) | 2017-08-01 |
| WO2016073767A1 (en) | 2016-05-12 |
| SG11201703717SA (en) | 2017-06-29 |
| RU2017118569A (ru) | 2018-12-06 |
| US20160130297A1 (en) | 2016-05-12 |
| EP3215179A4 (en) | 2018-07-25 |
| AU2015343025A1 (en) | 2017-06-08 |
| KR20170094184A (ko) | 2017-08-17 |
| US10266560B2 (en) | 2019-04-23 |
| CA2966885A1 (en) | 2016-05-12 |
| MX2017005935A (es) | 2018-01-11 |
| BR112017009657A2 (pt) | 2018-01-23 |
| RU2017118569A3 (zh) | 2019-02-27 |
| JP2017533923A (ja) | 2017-11-16 |
| PH12017500828A1 (en) | 2017-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243930A1 (zh) | 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法 | |
| HK1244708A1 (zh) | 作爲fxr/tgr5激動劑的胆汁酸類似物及其使用方法 | |
| ZA201908293B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| HK1245100A1 (zh) | 作為fxr/tgr5激動劑的膽汁酸類似物及其使用方法 | |
| ZA202102769B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| IL265803A (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| IL255269A (en) | Preparations of obeticholic acid and methods of use | |
| IL249223A0 (en) | Mth1 inhibitors for the treatment of inflammatory and autoimmune conditions | |
| IL247529A0 (en) | Preparations of choline ester lipoic acid and methods of use | |
| PL3252489T3 (pl) | Urządzenie i sposób oceny stanu akumulatora | |
| IL264628A (en) | Combination of fxr agonists | |
| GB201419472D0 (en) | Method of using and electrochemical device | |
| SG11201609485RA (en) | Detection of acrylic acid | |
| SG11201702174UA (en) | Setting method for conductive object of electrochemical test strip | |
| GB201408738D0 (en) | Components and methods for formulation of components |